




The relative strengths and weaknesses of VYNE Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VYNE Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 137% points. The greatest weakness of VYNE Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 20% points.

The company's Economic Capital Ratio, given in the ranking table, is 376%, being 127% points above the market average of 250%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	139,500	Assets	139,928
Cost of Goods Sold	0	Liabilities	9,551
Intangible Assets	0	Expenses	65,175
Liabilities, Current	9,544	Revenues	10,640
Liabilities, Non-Current	7.0	Stockholders Equity	130,377
Other Assets	282	Net Income	-51,445
Other Compr. Net Income	-45	Comprehensive Net Income	-51,468
Other Expenses	0	BaseVar	114,214
Other Liabilities	0	ECR before Limited Liability	311%
Other Net Income	3,090	Economic Capital Ratio	376%
Other Revenues	10,640		
Property and Equipment	146		
Research and Development	52,989		
Selling, General and Administrative Expense	12,186		